fibrinogen binding inhibitor peptide

Fibrinogen Binding Inhibitor Peptide, a synthetic dodecapeptide, represents the specific platelet receptor recognition site of the human fibrinogen g-chain (residues 400-411).

MLCK inhibitor peptide 18 acetate is a selective competitive inhibitor of myosin light chain kinase (IC50 = 50 nM). Displays 4000-fold selectivity over CaM kinase II and does not inhibit PKA. Cell permeable.

PKG inhibitor peptide TFA (82801-73-8 free base) is an inhibitor of ATP-competitive cGMP-dependent protein kinase (PKG).

Lyn peptide inhibitor acetate is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor can be used for study of asthma, allergic, and other eosinophilic disorders.

Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin

SLLK, Control Peptide for TSP1 Inhibitor acetate is a control peptide for LSKL.

Bax inhibitor peptide V5 acetate (Bax inhibitor peptide V5 acetate（579492-81-2 free base)) is a Bax-mediated apoptosis inhibitor, used for cancer treatment.

PKCε Inhibitor Peptide acetate is a selective PKCε inhibitor containing the site for its specific receptor for activated C kinase (RACK). PKCε Inhibitor Peptide acetate inhibits the translocation of PKCε, but not α-, β-, and δPKC.

Bax inhibitor peptide V5 (BIP-V5) is a Bax-mediated apoptosis inhibitor exhibiting anticancer activity.

Myristoylated PKCθ pseudosubstrate peptide inhibitor is a synthetic peptide utilized to investigate the mechanism of action of protein kinase C theta (PKCθ) [1].

PKCβII Peptide Inhibitor I, a specific PKCβII inhibitor, exhibits cardioprotective properties in a rat cardiac ischemia/reperfusion injury model and mitigates vascular endothelial dysfunction [1].

Rac1 Inhibitor F56, control peptide acetate is a control peptide version of Rac1 Inhibitor; comprises residues 45-60 of Rac1 with Trp56 replaced by Phe. Does not affect GEF-Rac1 interaction.

Biotin-labeled Hyaluronan-binding Peptide is a biologically active peptide conjugated with biotin via a C-terminal GGGSK linker. It interacts with the non-sulfated glycosaminoglycan hyaluronan (HA), prominent in the extracellular matrix and on cellular surfaces, involved in processes such as fertilization, embryonic development, wound healing, angiogenesis, leukocyte migration, and cancer metastasis. The peptide impedes HA's interaction with CD44 receptors and curtails T cell proliferation.

Integrin Binding Peptide, derived from fibronectin, holds the potential as an essential component for preparing PEG hydrogels.

PKCα (C2-4) inhibitor peptide is a specific antagonist to PKCα, preventing the α1A-adrenoreceptor agonist A-61603 [1] from inhibiting I_Kr.

Novel cyclic peptide that disrupts interaction between GluR6 and PSD-95

Protein kinase inhibitor peptide matches the inhibitory domain of the heat-stable protein kinase inhibitor.

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.

The compound is a negative control peptide for the Bax inhibitor peptides V5 and P5.

Myristoyl-MEK1 Derived Peptide Inhibitor 1, the myristoylated variant of MEK1 Derived Peptide Inhibitor 1, effectively inhibits ERK activation, demonstrating an inhibitory concentration (IC50) of 10 μM [1].

A2-Binding peptide has involved in the assembly of MHC Class I molecules.

ErbB-2-binding peptide (HER2-binding peptide), a tumor-targeting peptide, shows significant potential for cancer research applications [1].

FSH receptor-binding inhibitor fragment (bi-10) is a potent antagonist that inhibits the binding of follicle-stimulating hormone (FSH) to its receptor (FSHR), modifying FSH activity at the receptor level. It suppresses ovulation and induces follicular atresia in mice. Furthermore, this compound holds potential for curbing ovarian cancer carcinogenesis by reducing the overexpression of FSHR and estrogen receptor beta (ERβ) in the ovaries [1].

Calmodulin Binding Peptide 1, a potent CaM-binding peptide with picomolar (pM) affinity, originates from smooth muscle myosin light-chain kinase (MLCK peptide). It effectively blocks inositol trisphosphate (IP3)-induced calcium (Ca2+) release [1].

PKG inhibitor peptide TFA is an ATP-competitive antagonist of cGMP-dependent protein kinase (PKG) with a K_i value of 86 μM [1].

Cell-permeable inhibitor of Lyn-dependent effects of the IL-5 receptor. Blocks binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors, blocking Lyn activation. Inhibits IL-5 receptor-mediated eosinophil differentiation and survival in

SLLK is a control peptide for LSKL.

PKCε Inhibitor Scramble Peptide consists of the same amino acid sequence as the PKCε inhibitor peptide, but in a randomized order.

MEK1 Derived Peptide Inhibitor 1, a peptide inhibitor, prevents the in vitro activation of ERK2 by MEK1, exhibiting an inhibitory concentration (IC 50) of 30 μM. It is utilized in the study of cell-permeable [1].

Competitive inhibitor of cGMP-dependent protein kinase (PKG); analog of a substrate peptide corresponding to a phosphorylation site of histone H2B. Competes with synthetic substrates (Ki = 86 mM) but does not inhibit phosphorylation of intact histones by

Control peptide version of Rac1 Inhibitor; comprises residues 45-60 of Rac1 with Trp56 replaced by Phe. Does not affect GEF-Rac1 interaction.

Lyn Peptide Inhibitor TFA is a powerful, cell-permeable inhibitor specifically targeting the Lyn-coupled IL-5 receptor signaling pathway, without affecting alternative signaling pathways. It effectively prevents Lyn activation and impedes the association between Lyn tyrosine kinase and the βc subunit of IL-3/GM-CSF/IL-5 receptors. This compound is utilized in the investigation of asthma, allergic reactions, and various eosinophilic conditions [1].

Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen, a soluble plasma protein and cofactor in platelet activation, is converted to fibrin in a thrombin-catalyzed reaction.

Myristoylated PKCε inhibitor peptide (Myr-PKCε-) is a cell-permeable inhibitor consisting of a peptide linked to myristic acid that specifically inhibits protein kinase C epsilon (PKCε), consequently diminishing nitric oxide (NO) release in cultured human umbilical vein endothelial cells (HUVECs) [1].

PDZ1 Domain Inhibitor Peptide TFA, a cyclic peptide featuring a β-Ala lactam side chain linker, specifically targets the PDZ1 domains of postsynaptic density protein 95 (PSD-95). It effectively disrupts the GluR6/PSD-95 interaction, competing against the C terminus of GluR6 for the PDZ1 domain with high efficiency [1].

PKC-ε Translocation Inhibitor Peptide is a selective modulator that controls the FcγR-mediated internalization rate of opsonized beads without affecting FcαR trafficking [1].

Selective competitive inhibitor of myosin light chain kinase (IC50 = 50 nM). Displays 4000-fold selectivity over CaM kinase II and does not inhibit PKA. Cell permeable.

Renin Inhibitor Peptide, Rat, is a biologically active peptide that functions as a specific inhibitor of rat renin.

PTBP1-RNA-binding inhibitor P6 (PTBP1 α3-helix derived peptide P6) TFA is a stapled peptide that inhibits the splicing factor PTBP1 by binding to its RNA recognition motif [1], thereby targeting alternative splicing events regulated by this protein.